UK markets close in 2 hours 24 minutes
  • FTSE 100

    7,227.27
    +22.72 (+0.32%)
     
  • FTSE 250

    22,956.29
    +24.63 (+0.11%)
     
  • AIM

    1,229.60
    -4.59 (-0.37%)
     
  • GBP/EUR

    1.1857
    +0.0057 (+0.48%)
     
  • GBP/USD

    1.3752
    -0.0008 (-0.06%)
     
  • BTC-GBP

    45,616.13
    +1,403.46 (+3.17%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • DOW

    35,677.02
    +73.92 (+0.21%)
     
  • CRUDE OIL

    84.91
    +1.15 (+1.37%)
     
  • GOLD FUTURES

    1,805.10
    +8.80 (+0.49%)
     
  • NIKKEI 225

    28,600.41
    -204.44 (-0.71%)
     
  • HANG SENG

    26,132.03
    +5.10 (+0.02%)
     
  • DAX

    15,591.64
    +48.66 (+0.31%)
     
  • CAC 40

    6,721.29
    -12.40 (-0.18%)
     

Kizoo Portfolio Company Underdog Closes $10M Financing Round

·3-min read

DGAP-News: KIZOO Technology Capital GmbH / Key word(s): Financing
23.09.2021 / 13:00
The issuer is solely responsible for the content of this announcement.

Kizoo Portfolio Company Underdog Closes $10M Financing Round

Mountain View, CA, U.S., September 23, 2021 - Underdog Pharmaceuticals, a key investment of Michael Greve's rejuvenation biotech VC Kizoo, has closed a $10 million round of capital. Kizoo led the company's Series Seed II round, which saw participation from both existing and new investors.

Accounting for up to 40% of deaths in Europe and the United States, cardiovascular disease, heart attacks, and strokes are by far the world's most life-threatening conditions. Their primary cause is atherosclerosis-the buildup of plaque in the arterial walls. Underdog's engineered synthetic carbohydrate compound, UDP-003, is designed to target and remove toxic oxidized cholesterol, a key driver of arterial plaque accumulation. Underdog was recently awarded the Innovation Passport under the United Kingdom's Innovative Licensing and Access Pathway (ILAP). This will enable faster patient access to its groundbreaking treatment for the prevention of heart attacks and stroke. The company expects to begin clinical trials in 2023.

Mike Kope, Underdog Co-CEO, said: "The ILAP award together with the new funds will enable us to further advance to deliver a simple and affordable preventive therapy for the world".

"We are really into this. This is the first deployment from our $360M commitment to fund the most promising rejuvenation startups through follow-up rounds to advance the therapies from clinical development to public availability", said Frank Schueler, Managing Director of Kizoo Technology Capital.

About KIZOO

Kizoo provides mentoring, seed and follow-on financing with a focus on rejuvenation biotech. Having been entrepreneurs, VCs, and mentors in both high-growth tech and biotech companies ourselves for many years with multiple exits and massive value created for the founders, Kizoo now brings this experience to the emerging field of rejuvenation biotech. We see it as a young industry that will eventually outgrow today's largest technology markets.

As part of Michael Greve's Forever Healthy Group, Kizoo directly supports the creation of startups turning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Underdog, Revel Pharmaceuticals, Elastrin Therapeutics, and others.

Forever Healthy's other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world's cutting-edge medical knowledge, funding research projects on the root causes of aging and hosting the annual Undoing Aging Conference.

Further information, please visit: www.kizoo.com and www.forever-healthy.org.

About Underdog

Underdog Pharmaceuticals, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.underdogpharma.com.

Media Contact for Kizoo:

Frank Schueler
Managing Director
Kizoo Technology Capital
fs@kizoo.com

Media Contact for Underdog:
Mike Kope
Co-CEO
Underdog Pharmaceuticals Inc
press@underdogpharma.com


23.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

KIZOO Technology Capital GmbH

Amalienbadstraße 41

76227 Karlsruhe

Germany

Phone:

+49 721 5160 0

E-mail:

info@kizoo.com

Internet:

www.kizoo.com

EQS News ID:

1235445


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting